Shah Rajesh, Talele Gitanjali, Kasinathan Nirmal Kumar, Barkume Madan, Kode Jyoti
Department of Research, Biosimilia Private Limited, Mumbai, India.
Department of Research, Biosimilia Private Limited, Mumbai, India.
J Ayurveda Integr Med. 2024 Nov-Dec;15(6):101015. doi: 10.1016/j.jaim.2024.101015. Epub 2024 Dec 2.
Xenografts in immunodeficient mice play a pivotal role in testing novel anti-cancer treatments. Xenograft models expedite the drug discovery process, offering a cost-effective alternative to conventional animal models and providing essential data for clinical trials. We have followed the approach described by the Developmental Therapeutics Program of the National Cancer Institute (NCI), USA to investigate the therapeutic responses.
In this research, potentized preparations derived from biomaterial, referred to as nosodes, have exhibited promising effectiveness against cancer in laboratory experiments. This study seeks to further substantiate these findings by employing animal models.
Potentized preparations from category nosodes sourced from biomaterials of HIV, Cancer tissue, Hepatitis C and a combination underwent testing within the NCI's preclinical evaluation protocols using Xenograft models (HOP62). All the experimental mice were randomly assigned to one of six groups (n = 6), including vehicle and positive controls. These preparations were administered orally at a dosage of 0.1 ml, five days a week, over a four-week period. The mice were closely monitored at regular intervals for 32 days, with observations regarding changes in body weight, tumor volume, morbidity, and mortality. Relative tumor volume (RTV) was calculated as the tumor volume on the day of measurement divided by the tumor volume on day 1.
The groups treated with Hepatitis C 30c and HIV 100c nosodes have not shown effect with respect to Relative Tumor Volume (RTV). Evidence of significant tumor regression was observed for RTV on day 30 in groups treated with HIV nosode 30c (P = 0.002), and Cancer nosode 30c (P = 0.005). Percentage Survival was noted better in HIV nosode 30c treated group from day 25, however, in other groups survival percentage remained constant. Varied animal body weight in all groups was noted. Significant differences in tumor volume with respect to time in all treated groups were observed.
Results are suggestive of tumor regression which is encouraging to undertake further clinical trials to explore the anticancer potential of HIV nosode and Cancer nosode.
免疫缺陷小鼠中的异种移植在测试新型抗癌治疗方法中起着关键作用。异种移植模型加快了药物发现过程，为传统动物模型提供了一种经济高效的替代方案，并为临床试验提供了重要数据。我们采用了美国国立癌症研究所（NCI）发育治疗项目所描述的方法来研究治疗反应。
在本研究中，源自生物材料的增效制剂，即疫病体质疗法药物，在实验室实验中已显示出有前景的抗癌效果。本研究旨在通过动物模型进一步证实这些发现。
从HIV、癌组织、丙型肝炎的生物材料以及一种组合中获取的疫病体质疗法药物的增效制剂，在NCI的临床前评估方案中使用异种移植模型（HOP62）进行测试。所有实验小鼠被随机分配到六个组之一（n = 6），包括赋形剂对照组和阳性对照组。这些制剂以0.1毫升的剂量口服，每周五天，持续四周。在32天内定期密切监测小鼠，观察体重、肿瘤体积、发病率和死亡率的变化。相对肿瘤体积（RTV）计算为测量当天的肿瘤体积除以第1天的肿瘤体积。
用丙型肝炎30c和HIV 100c疫病体质疗法药物治疗的组在相对肿瘤体积（RTV）方面未显示出效果。在用HIV疫病体质疗法药物30c（P = 0.002）和癌疫病体质疗法药物30c（P = 0.005）治疗的组中，在第30天观察到RTV有显著肿瘤消退的证据。从第25天起，HIV疫病体质疗法药物30c治疗组的存活率更高，然而，其他组的存活率保持不变。注意到所有组的动物体重各不相同。观察到所有治疗组的肿瘤体积随时间有显著差异。
结果表明有肿瘤消退，这鼓励进行进一步的临床试验，以探索HIV疫病体质疗法药物和癌疫病体质疗法药物的抗癌潜力。
